文献速递银屑病与炎症性皮肤病皮肤感染

银屑病系统治疗中结核、脑膜炎、念珠菌病及真菌感染风险:基于BADBIR数据的全国队列研究

Risks of tuberculosis, meningitis, candidiasis, and fungal infections among patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data.
PubMed 文献 · Br J Dermatol · 2026-09-15

该研究利用BADBIR登记数据(2007-2024),纳入18,635例银屑病患者共40,930个治疗疗程,随访118,018人年。结果显示结核和脑膜炎罕见且多与TNF-α抑制剂相关,而IL-17抑制剂单独使用时念珠菌感染风险显著高于其他系统治疗。

要点

  • 结核和脑膜炎罕见,多与TNF-α抑制剂(尤其阿达木单抗)相关。
  • IL-17抑制剂念珠菌感染风险显著高于其他系统治疗,IRR范围2.67至4.65。
  • 非念珠菌性真菌感染在各治疗组间无显著差异。

核心结论

  • 结核和脑膜炎罕见,需更长随访以明确新药风险;念珠菌感染在IL-17抑制剂使用者中风险增加。

研究设计与样本

  • 全国性队列研究,使用BADBIR登记数据(2007-2024),纳入18,635例接受系统治疗的成人银屑病患者,共40,930个治疗疗程,随访118,018人年。

主要发现

  • 总体发病率:结核0.19/1000人年(95%CI 0.12-0.29),脑膜炎0.25/1000人年(95%CI 0.16-0.35),真菌感染7.53/1000人年(95%CI 7.05-8.05)。
  • 随访期间报告22例结核、29例脑膜炎、888例真菌感染(其中450例念珠菌病)。
  • 大多数结核和脑膜炎病例与TNF-α抑制剂相关,尤其是阿达木单抗;脑膜炎主要为病毒性,结核主要为肺结核。
  • 脑膜炎30天死亡率少于5例。
  • IL-17抑制剂单药治疗对比其他系统治疗组,念珠菌感染IRR从2.67(95%CI 1.33-5.36,对比阿普米司特)到4.65(95%CI 3.46-6.24,对比IL-12/23抑制剂)。

临床怎么用

  • 使用TNF-α抑制剂(尤其阿达木单抗)者应警惕结核和脑膜炎风险。
  • 使用IL-17抑制剂者需关注念珠菌感染风险,必要时进行监测和管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic treatments for psoriasis confer differential risk profiles for infections such as tuberculosis, meningitis, candidiasis and other fungal infections. However, real-world comparative data including IL-17 and 23 inhibitors remain limited. METHODS: We conducted a nationwide cohort study using data from British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) from 2007 to 2024. Adults with psoriasis receiving systemic treatments were included and followed from treatment initiation until treatment discontinuation, death, or last available follow-up data. Primary outcomes included tuberculosis, meningitis, candidiasis and other fungal infections. Incidence rates per 1000 person-years were calculated and incidence rate ratios (IRRs) were estimated using doubly robust interval-based Poisson regression model. Entropy balancing method was used to achieve covariate balance across treatment groups and multiple imputation was used to handle missing baseline data. RESULTS: A total of 40,930 treatment episodes from 18,635 patients contributing 118,018 person-years of follow-up were included in this analysis. During the follow-up, 22 tuberculosis cases, 29 meningitis cases, and 888 fungal infection cases including 450 candidiasis were reported. The overall incidence rates were 0.19 (95% CI 0.12 to 0.29) for tuberculosis, 0.25 (95% CI 0.16 to 0.35) for meningitis, and 7.53 (95% CI 7.05 to 8.05) for fungal infections per 1000 person-years. Most tuberculosis and meningitis cases were associated with TNF-α inhibitors, particularly adalimumab. Meningitis was predominantly viral and tuberculosis was largely pulmonary. 30-day mortality was observed in fewer than 5 cases in meningitis. IL-17 inhibitors alone exhibited increased risk of candidiasis compared to all other systemic treatment groups with IRRs ranging from 2.67 (95% CI 1.33 to 5.36) versus apremilast to 4.65 (95% CI 3.46 to 6.24) versus IL-12/23 inhibitor. Individual IL-17 inhibitors did not exhibit significant differences in the candidiasis risk. With fungal infections other than candidiasis, no statistically significant differences were observed between treatment groups. CONCLUSIONS: In this large cohort study, tuberculosis and meningitis were rare and longer-term follow-up is required to further characterise the risk with newer treatments. Candidiasis and fungal infections were more common with increased risks among patients receiving IL-17 inhibitors.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Bright HRB, Smith CH, Laws P, et al. Risks of tuberculosis, meningitis, candidiasis, and fungal infections among patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data. Br J Dermatol. 2026. PMID: 42740637. doi:10.1093/bjd/ljag397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。